BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients
Share
Why It Matters
BeOne Medicines shared test results for a new cancer medicine. The drug helped over one third of very sick patients without causing big problems.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.